artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography

AI-CAD marked axillary lymph node and region in right upper outer quadrant (arrows and thin line outlining both sites) and assigned an abnormality score of 28%.


August 11, 2021 — According to an open-access Editor’s Choice article in the American Journal of Roentgenology (AJR), artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography.

“After BCT, adjunct digital breast tomosynthesis (DBT) or AI-CAD reduced recall rates and improved accuracy in the ipsilateral and contralateral breasts compared with digital mammography (DM),” wrote lead investigator Jung Hyun Yoon. “In the ipsilateral breast, addition of AI-CAD resulted in lower recall rate and higher accuracy than addition of DBT.”

Yoon and colleagues’ single-center retrospective study included 314 women (mean age, 53.2 years; 4 with bilateral breast cancer) who underwent BCT followed by DBT (mean interval from surgery to DBT, 15.2 months). Three breast radiologists independently reviewed images in three sessions: DM, DM with DBT, and DM with AI-CAD. Recall rates and diagnostic performance were compared between these three sessions using readers’ mean results.

Among these 314 women, the mean ipsilateral breast recall rate among all three readers was lower (p<.001) for DM with AI-CAD (1.9%) than for DM with DBT (4.1%). In the ipsilateral breast, both mean accuracy (97.0% vs 94.8%, p=.02) and specificity (98.3% vs 96.1%, p=.003) were higher for DM with AI-CAD than for DM with DBT, respectively.

Acknowledging that data regarding other AI-CAD applications for the post-BCT breast are scarce, “our study shows that recall rates decrease significantly when DBT or AI-CAD are used as adjuncts to DM for surveillance of the ipsilateral and contralateral breasts in women with a personal history of breast cancer after BCT,” the authors of this AJR article concluded.

For more information: www.arrs.org


Related Content

News | Stroke

Dec. 18, 2025 — Brainomix, a provider of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced ...

Time December 24, 2025
arrow
News | Information Technology

Dec. 16, 2025 — McCrae Tech has launched the world’s first health AI orchestrator called Orchestral. It is a health ...

Time December 23, 2025
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | RSNA 2025

Dec. 12, 2025 — At RSNA 2025, United Imaging Intelligence (UII), the AI-focused subsidiary of United Imaging Group ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
Feature | Radiation Oncology | Kyle Hardner

Genomics has guided personalized cancer treatments for the past two decades. Now, AI biomarkers are expanding the field ...

Time December 09, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Women's Health

Dec. 1, 2025 — ScreenPoint Medical has completed a commercial agreement making its Transpara breast-imaging AI portfolio ...

Time December 03, 2025
arrow
Subscribe Now